ClinicalTrials.gg
CompletedNCT04654364Updated Oct 16, 2026

Lung Cancer Registry

An observational study in Lung Cancer, NSCLC Stage IV and NSCLC, Stage III, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Completed at 3 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Observational

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
290
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Lung Neoplasms with a site in Austria — 17 open to participants now, 22 under way, 10 of them phase 3. Lung Neoplasms · Austria.

Enrollment
14th of 17
290 · median 770
Started
2020
with 2 others
Observational
17 of 69
5 open now
Registered
44th of 69
by date
Lead sponsor
2 of 69
Arbeitsgemeinschaft medikamentoese Tumortherapie

Among the 69 studies in Lung Neoplasms with a site in Austria, this one is the 14th largest by enrollment of the 17 observational ones that give a count, is one of 3 that started in 2020, is one of 17 observational ones, and was the 44th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

17 of the 69 studies in Lung Neoplasms with a site in Austria are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Lung Neoplasms with a site in Austria, or all of them as a file.
02

Study summary

Lung cancer is the second most common cancer in Austria with 2.868 men and 2.009 women diagnosed in 2016. Reflecting the high mortality of this disease, 2.415 men and 1.534 women died from lung cancer. Therefore, lung cancer is the most common reason for cancer associated death in men and second most common reason in women.

This malignant disease can be divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is a paradigm for personalized medicine, with an increasing number of targetable gene alterations. Despite this growing diversity of molecular subtypes, in most patients no targetable mutation can be detected. For these patients check-point inhibitors with or without chemotherapy is the mainstay of the initial tumor therapy. Until recently, little progress has been made in the treatment of SCLC in last decades. Recently, an overall survival benefit by the addition of an immune-checkpoint inhibitor to first-line chemotherapy for advanced SCLC has been reported.

Despite the progress in the treatment of NSCLC, the performance of predictive biomarkers is weak. Therefore, the development of more precise prediction models is of great importance for the progress of personalized treatment strategies.

Read the detailed description

This registry is designed as multicenter observational cohort of patients with lung cancer. Patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. This patient follow-up data will be obtained until patient death or loss to follow-up.

For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. Only routine data, which has already been recorded in the patient's medical chart, is transferred to the electronic Case Report Forms. To maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patient's medical and other registry information throughout the lifetime of the registry.

A written consent must be obtained prior to the input of data. No informed consent is required from deceased patients.

Data will be collected from all sites willing to participate.

03

Conditions studied

  • Lung Cancer
  • NSCLC Stage IV
  • NSCLC, Stage III
  • SCLC, Extensive Stage
  • SCLC, Limited Stage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The registry will be made available for all disciplines and physicians caring for cancer patients with locally advanced or metastatic lung cancer in Austria. In a first step patients with diagnosis after 01.01.2019 will be included. In a second step the registry will be expanded to include patients with diagnosis before 01.01.2019.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • stage III A-C and IV A-B NSCLC
  • limited disease (LD) and extensive disease (ED) SCLC)
  • patients ≥ 18 years

Exclusion criteria

Exclusion Criteria:

- Due to the non-interventional design of the registry there are no specific exclusion criteria.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
290 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. General characteristics

    To describe the general characteristics of advanced or metastatic stage patients in Austria (Stage III A-C and IV A-B NSCLC, limited disease (LD) and extensive disease (ED) SCLC)

    Time frame: 10 years

  2. Molecular testing

    To describe molecular testing in patients with advanced or metastatic lung cancer * number of patients with molecular testing * methods for molecular testing * number of patients with PD-L1 testing * PD-L1 % range per disease stage * PD-L1 test antibody used * number of genes tested * number of patients with at least one mutation identified * number of patients with at least one druggable target identified

    Time frame: 10 years

  3. Characterize subgroups

    To describe and characterize subgroups * Number of patients with NSCLC * Number of patients that receive immune-checkpoint inhibitors * Number of patients with targetable/druggable mutations

    Time frame: 10 years

  4. Treatment duration

    To describe duration of treatment

    Time frame: 10 years

  5. Treatment frequency

    To describe frequency of treatment

    Time frame: 10 years

  6. Degree of treatment response

    To describe degree of treatment response in %

    Time frame: 10 years

  7. Treatment sequence

    To describe sequence of use of various treatments

    Time frame: 10 years

  8. Outcome OS

    To describe patient outcome by means of overall survival (OS) in %

    Time frame: 10 years

  9. Outcome PFS

    To describe patient outcome by means of progression free survival (PFS) in %

    Time frame: 10 years

07

Study locations

3 sites
  • Universitätsklinik für Innere Medizin III, PMU Salzburg
    Salzburg, State of Salzburg 5020, Austria
  • Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / Universitätskliniken
    Innsbruck, Tyrol 6020, Austria
  • Kepler Universitätsklinikum GmbH, Med. Campus III, Klinik für Lungenheilkunde / Pneumologie
    Linz, Upper Austria 4021, Austria
08

References and documents

Individual participant data

Plan to share: No — The datasets generated and/or analyzed during the current study are not publicly available but are available from AGMT (Austrian Group Medical Tumor Therapy) upon reasonable request. Requests for access to these data should be directed to AGMT via office@agmt.at.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in May 2026, 68 months.

Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's 68 months is close to that.

Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Aug 2030 → May 2026 and completion Aug 2030 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2020
First posted
Dec 4, 2020
StartActual
Aug 18, 2020
Primary completionActual
May 6, 2026was Aug 2030
CompletionActual
May 6, 2026was Aug 2030
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 Austria)
  • Universitätsklinik für Innere Medizin III, PMU Salzburg · Salzburg, Austria
  • Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / Universitätskliniken · Innsbruck, Austria
  • Kepler Universitätsklinikum GmbH, Med. Campus III, Klinik für Lungenheilkunde / Pneumologie · Linz, Austria
Show 3 removed
  • Kepler Universitätsklinikum GmbH, Med. Campus III, Klinik für Lungenheilkunde / Pneumologie · Linz, Austria
  • Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / Universitätskliniken · Innsbruck, Austria
  • Universitätsklinik für Innere Medizin III, PMU Salzburg · Salzburg, Austria
Oct 16, 2026
Primary completion
Aug 2030→May 6, 2026 (actual)
Oct 16, 2026
Study completion
Aug 2030→May 6, 2026 (actual)
Oct 16, 2026
Enrollment
500 (estimated)→290 (actual)
Oct 16, 2026
Eligibility
Revised
Oct 16, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedToxicity of treatmentTime frame: 10 years
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    3 sites added, 3 sites removed
    Show 3 added (3 Austria)
    • Universitätsklinik für Innere Medizin III, PMU Salzburg · Salzburg, Austria
    • Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / Universitätskliniken · Innsbruck, Austria
    • Kepler Universitätsklinikum GmbH, Med. Campus III, Klinik für Lungenheilkunde / Pneumologie · Linz, Austria
    Show 3 removed
    • Kepler Universitätsklinikum GmbH, Med. Campus III, Klinik für Lungenheilkunde / Pneumologie · Linz, Austria
    • Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / Universitätskliniken · Innsbruck, Austria
    • Universitätsklinik für Innere Medizin III, PMU Salzburg · Salzburg, Austria
    Primary completion Aug 2030→May 6, 2026 (now actual)
    Study completion Aug 2030→May 6, 2026 (now actual)
    Enrollment 500 (estimated)→290 (actual)
    Eligibility Revised
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedToxicity of treatmentTime frame: 10 years
    + 7 other changes: identifiers, verification date, responsible party, oversight details, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04654364
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Responsible party
Sponsor
First posted
Dec 4, 2020
Start date
Aug 18, 2020
Primary completion
May 6, 2026
Completion
May 6, 2026
Last update
Oct 16, 2026

Study contacts

Richard Greil, MD
study chair · AGMT gemeinnützige GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion